BusinessKura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017By Nasdaq OMXFeb 27, 2017, 12:30 PM UTC
